Holen Sie sich die Stockscreener-App
6.76
2.89%
0.19
Handel nachbörslich:
6.63
-0.13
-1.92%
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Fulcrum Therapeutics (FULC) Steadies Near $6.57 as Biotech Sector Waits for CatalystSocial Momentum Signals - Newser
Fulcrum Therapeutics Q1 2026 Earnings: Narrowed Loss Exceeds Analyst ExpectationsEarnings Season Outlook - Newser
Fulcrum Therapeutics Q1 2026 Earnings: Narrowing Losses as Pipeline AdvancesPopular Market Picks - Newser
After plunging 21.5% in 4 weeks, here's why the trend might reverse for Fulcrum Therapeutics (FULC) - MSN
After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC) - Yahoo Finance Singapore
Fulcrum Therapeutics shares climb after Q1 earnings outperform expectations - MSN
Fulcrum Therapeutics, Inc.Common Stock (NQ: FULC - FinancialContent
Nantahala Capital files: 3,050,040 shares (4.58%) in THERAPEUTICS, INC. (FULC) - Stock Titan
Fulcrum Therapeutics (FULC) amendment shows 5.25M-share, 7.9% position - Stock Titan
Fulcrum Therapeutics (FULC) Stock Analysis: Falls -6.05%, Watching $6.35 2026-05-15Trend Signals - newser.com
Fulcrum Therapeutics (FULC) Holds $$7.25 — Direction Awaited 2026-05-14Debt Free Stocks - Newser
Bank of America Securities Keeps Their Sell Rating on Fulcrum Therapeutics (FULC) - The Globe and Mail
Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy Recommendation - MSN
Fulcrum Therapeutics (FULC.US) is scheduled to release its earnings report before the market opens on April 27. - Moomoo
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics (FULC) narrows Q1 loss 18% more than expected despite zero revenue; shares rise 2%.Growth Phase - newser.com
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Two new Fulcrum hires get 55,500 stock options at $7.02 a share - Stock Titan
What metric defines Fulcrum Therapeutics (FULC) success this quarter | Fulcrum Therapeutics Beats EPS ForecastTrending Stock Ideas - newser.com
FULC SEC FilingsFulcrum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
FULC.O Technical Analysis & Stock Price Forecast - Intellectia AI
Fulcrum Therapeutics (NASDAQ:FULC) Rating Increased to Sell at Wall Street Zen - MarketBeat
Fulcrum Therapeutics (FULC) director receives 64,000 stock options at $8.08 strike price - Stock Titan
Fulcrum Therapeutics (NASDAQ: FULC) director files Form 3 with no shares owned - Stock Titan
[ARS] Fulcrum Therapeutics, Inc. SEC Filing - Stock Titan
Executive pay and auditor vote at Fulcrum Therapeutics (NASDAQ: FULC) - Stock Titan
HC Wainwright Issues Optimistic Estimate for FULC Earnings - MarketBeat
Facioscapulohumeral Muscular Dystrophy Market: Pharma Pipeline Fuels Rapid Expansion – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: Pharma - openPR.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
FULC Should I Buy - Intellectia AI
Fulcrum Therapeutics Shares Surge After Beating Q1 Earnings Estimates - HarianBasis.co
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
A Quick Look at Today's Ratings for Fulcrum Therapeutics(FULC.US), With a Forecast Between $10 to $25 - Moomoo
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2026 Earnings Call Transcript - Insider Monkey
Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap DownTime to Sell? - MarketBeat
Fulcrum Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Fulcrum Therapeutics, Inc. Q1 2026 Financial Results and Forward-Looking Statements Overview - Minichart
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fulcrum Therapeutics Reports Positive Pociredir Data in Sickle Cell Disease, Strong Cash Position Through 2029 - Minichart
Value Trap or Opportunity? Fulcrum Therapeutics (FULC) Q1 2026 E - GuruFocus
Fulcrum Therapeutics (FULC) CFO Alan Musso to Retire This Year - GuruFocus
Fulcrum (FULC) Reports Financial Update and Clinical Progress - GuruFocus
Earnings call transcript: Fulcrum Therapeutics reports Q1 2026 earnings beat - Investing.com
Earnings call transcript: Fulcrum Therapeutics reports Q1 2026 earnings beat By Investing.com - Investing.com Australia
Fulcrum Therapeutics Q1 2026 Earnings Call: Complete Transcript - Benzinga
Fulcrum Therapeutics, Inc. Announces Retirement of Alan Musso as Chief Financial Officer - marketscreener.com
Fulcrum Therapeutics (NASDAQ:FULC) Beats Q1 Estimates as Pociredir Data Fuels Optimism - ChartMill
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):